Combining Targeted Therapies for Lung Cancer
The FDA approved a combination of molecularly targeted therapeutics for use in combination to treat patients with metastatic non-small cell lung cancer.
Progress Against Cancer
The FDA approved a combination of molecularly targeted therapeutics for use in combination to treat patients with metastatic non-small cell lung cancer.
The May 2018 FDA approval of the immunotherapeutic durvalumab makes it the first treatment approved to reduce the risk of stage 3 lung cancer progressing.
The FDA approved a hormone therapy for treating men with nonmetastatic prostate cancer that has stopped responding to standard hormone therapy.
The FDA expanded the use of a molecularly targeted therapeutic to include the prevention of bone complications in patients with multiple myeloma.
The FDA approved a molecularly targeted therapeutic for treating certain patients who have breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutation.
The FDA expanded the use of a targeted therapy to include certain patients with two types of non-Hodgkin lymphoma.
The FDA approved a molecularly targeted therapeutic for adults with mantle cell lymphoma that has progressed despite at least one prior treatment.
The FDA approved the second of a revolutionary new type of immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy.
The FDA approved a molecularly targeted therapy for treating patients with a certain form of breast cancer.
The FDA expanded an immunotherapeutic to used for treating patients with hepatocellular carcinoma – the most common form of primary liver cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More